Clinical trial
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
NCT00255463 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00255463 |
|---|---|
| Title | Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study |
| Official title | Phase II, Placebo Controlled, Parallel Group, Double Blind, Randomised, Multicentre Trial Comparing the Anastrozole (Arimidex®) Placebo Combination to the Anastrozole - ZD1839 (Iressa™) Combination as Neoadjuvant Treatment in Postmenopausal Women With Stage I-IIIB Breast Cancer and Oestrogen… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Anastrazole, Gefitinib |
| Enrollment | 185 |
| Start date | Jan 1, 2004 |
| Completion | Nov 1, 2005 |
| First posted | Nov 21, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | Czechia, France, Hungary, Portugal, Spain, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: